Revance Therapeutics
Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.
HintMD is a cloud-based patient engagement and payments platform tailored for medical aesthetic practitioners. Established in 2014 and headquartered in Pleasanton, California, the company collaborates with board-certified physicians to identify gaps in patient care and enhance treatment experiences. HintMD's platform provides personalized treatment plan subscriptions that facilitate patient engagement, compliance, and improved clinical outcomes. By offering flexible monthly payment options, the platform aims to help consumers achieve their desired aesthetic results while ensuring that practices see increased patient satisfaction and revenue growth. With a focus on supporting over 30,000 physician-owned practices in the medical aesthetic industry, HintMD is dedicated to fostering better beauty outcomes for patients and improving business performance for practitioners.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.